Promoter methylation pattern of caspase-8, P16INK4A, MGMT, TIMP-3, and E-cadherin in medulloblastoma

被引:38
作者
Ebinger, M
Senf, L
Wachowski, O
Scheurlen, W
机构
[1] Cnopfsch Kinderklin, D-90419 Nurnberg, Germany
[2] Univ Tubingen, Inst Pathol, Dept Mol Pathol, D-7400 Tubingen, Germany
[3] Univ Hosp Giessen, Zentrum Kinderheilkunde & Jugendmed, Giessen, Germany
关键词
aberrant promoter methylation; medulloblastoma; caspase-8; p16(INK4A); MGMT; TIMP-3; CDH1;
D O I
10.1007/BF02893403
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Methylation of promoter regions of CpG-rich sites is an important mechanism for silencing of tumor suppressor genes (TSG). To evaluate the role of tumor suppressor genes caspase-8 (CASP8), TIMP-3, E-cadherin (CDH1), p16(INK4A), and MGMT in medulloblastoma tumorigenesis, 51 medulloblastomas ( 46 primary tumor specimens, 5 cell lines) were screened for methylation of promoter linked CpG-islands. For CASP8, we examined the 5' UTR region that has been shown to be associated with expression of CASP8. As detected by methylation specific PCR, methylation rate was low for TIMP-3 (3% of tumor samples; 1/5 cell lines), for MGMT (0% of tumor samples; 1/5 cell lines), for p16(INK4A) (2% of tumor samples; 2/5 cell lines) and for CDH1 (8% of tumor samples; 1/4 cell lines). CASP8, however, was methylated in 90% of tumor samples and 4/5 cell lines examined. Screening other tumor entities for CASP8 methylation, we found a similarly high level in 6 neuroblastoma cell lines in contrast to 5 osteosarcoma, 4 Ewing's sarcoma- and 6 non-embryonic tumor cell lines without any increased promoter methylation. From our results we conclude that methylation of the CASP8 5' UTR region may play a role in inactivation of CASP8 in neural crest tumors.
引用
收藏
页码:17 / 21
页数:5
相关论文
共 27 条
  • [1] Bachman KE, 1999, CANCER RES, V59, P798
  • [2] Expression and methylation of CASP8 in neuroblastoma:: Identification of a promoter region
    Banelli, B
    Casciano, I
    Croce, M
    Di Vinci, A
    Gelvi, I
    Pagnan, G
    Brignole, C
    Allemanni, G
    Ferrini, S
    Ponzoni, M
    Romani, M
    [J]. NATURE MEDICINE, 2002, 8 (12) : 1333 - 1335
  • [3] P16 deletion and mutation analysis in human brain tumors
    Barker, FG
    Chen, PC
    Furman, F
    Aldape, KD
    Edwards, MSB
    Israel, MA
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1997, 31 (1-2) : 17 - 23
  • [4] CLONING AND CHARACTERIZATION OF THE HUMAN INVASION SUPPRESSOR GENE E-CADHERIN (CDH1)
    BERX, G
    STAES, K
    VANHENGEL, J
    MOLEMANS, F
    BUSSEMAKERS, MJG
    VANBOKHOVEN, A
    VANROY, F
    [J]. GENOMICS, 1995, 26 (02) : 281 - 289
  • [5] Bobola MS, 2001, CLIN CANCER RES, V7, P613
  • [6] TRAIL receptor-2 signals apoptosis through FADD and caspase-8
    Bodmer, JL
    Holler, N
    Reynard, S
    Vinciguerra, P
    Schneider, P
    Juo, P
    Blenis, J
    Tschopp, J
    [J]. NATURE CELL BIOLOGY, 2000, 2 (04) : 241 - 243
  • [7] Aberrant CpG-island methylation has non-random and tumour-type-specific patterns
    Costello, JF
    Frühwald, MC
    Smiraglia, DJ
    Rush, LJ
    Robertson, GP
    Gao, X
    Wright, FA
    Feramisco, JD
    Peltomäki, P
    Lang, JC
    Schuller, DE
    Yu, L
    Bloomfield, CD
    Caligiuri, MA
    Yates, A
    Nishikawa, R
    Huang, HJS
    Petrelli, NJ
    Zhang, XL
    O'Dorisio, MS
    Held, WA
    Cavenee, WK
    Plass, C
    [J]. NATURE GENETICS, 2000, 24 (02) : 132 - 138
  • [8] Esteller M, 1999, CANCER RES, V59, P67
  • [9] Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
    Esteller, M
    Garcia-Foncillas, J
    Andion, E
    Goodman, SN
    Hidalgo, OF
    Vanaclocha, V
    Baylin, SB
    Herman, JG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (19) : 1350 - 1354
  • [10] Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells
    Friesen, C
    Herr, I
    Krammer, PH
    Debatin, KM
    [J]. NATURE MEDICINE, 1996, 2 (05) : 574 - 577